Access

Correspondence

Nature 416, 677 (18 April 2002) | doi:10.1038/416677d

Open Innovation Challenges

naturejobs

More science jobs
Post a job for free

Call for Elan to publish Alzheimer's trial details

Glenda M. Bishop1, Stephen R. Robinson2, Mark A. Smith1, George Perry1 & Craig S. Atwood1

  1. Institute of Pathology, Case Western Reserve University, Cleveland, Ohio 44106, USA
  2. School of Psychology, Psychiatry and Psychological Medicine, Monash University, Clayton, Victoria 3800, Australia

One potential route for therapy for Alzheimer's disease involves the immunization of patients against the amyloid-beta peptide, the major proteinaceous component that characterizes plaques in the brains of patients with this disease. Resulting from earlier research on mice, published in Nature1, 2, 3, Elan Pharmaceuticals recently began clinical trials of a vaccine, AN-1792, based on this approach.